BioNJ CEO Summit Brings Together Nearly 300 Influential Leaders

The Fourth Annual BioNJ CEO Summit that recently took place at the Bridgewater Marriott brought together some of the most influential leaders in the life sciences industry to share their knowledge, experiences and views on today’s challenging and evolving market access and commercialization environment. The lineup of speakers dove into the issues and considerations that need to be addressed along the development continuum, including raising capital, pricing, post-launch and politics.

Because Patients Can’t WaitSM, bringing new treatments and drugs to the patients who need them is always at the heart of our programs,” said BioNJ President and CEO Debbie Hart. “And, this year’s CEO Summit reflected that by facilitating vital conversations that need to happen to ensure ongoing medical innovation. Today’s environment is increasingly complex and the uncertainty of the election makes it even more ominous.”

One of the many highlights of the Summit included a luncheon presentation by Biotechnology Innovation Organization (BIO) President and CEO James Greenwood. During his Keynote address, Greenwood introduced ” Innovation Saves,” BIO’s multi-media campaign focused on biopharmaceutical innovation and its’ unique ability to help save lives and money. He rounded out his Keynote with a fireside chat led by Hart on his predictions on the 2016 Presidential Race and its impact on future medical innovation, access and pricing.

The diverse roster of speakers included:

  • Murray Aitken, Sr.Vice President & Executive Director, IMS Institute for Healthcare Informatics
  • Meg Alexander, Head, Issues Management Practice, inVentiv Health
  • Mark J. Alles, CEO, Celgene Corporation
  • Fedora Baloiu, Head of the Biopharmaceutical Practice, Houlihan Lokey’s Healthcare Group
  • Geert Cauwenbergh, Ph.D., Med. Sc., CEO, RXi Pharmaceuticals Corporation
  • Brett Davis, Principal, Deloitte Consulting & General Manager, ConvergeHEALTH
  • James Greenwood, President & CEO, Biotechnology Innovation Organization (BIO)
  • Robert Goldberg, Ph.D., Vice President and Co-Founder, Center for Medicine in the Public Interest
  • Sam Hall, Ph.D., Principal, Apple Tree Partners
  • Karin Hehenberger, M.D., Ph.D., Founder, Chairman & CEO, LYFEBULB
  • Jesper Høiland, Executive Vice President, U.S., Novo Nordisk
  • Lindsay McKenna, Ph.D., Associate Principal, McKinsey & Company
  • Daniel O’Connor, President, CEO & Director, Advaxis
  • Stelios Papadopoulos, Ph.D., Chairman, Biogen
  • Linda Pissott Reig, Esq., Shareholder, Buchanan Ingersoll and Rooney PC
  • Carlo Rizzuto, Ph.D., Partner, Versant Ventures
  • David Schwartz, Partner, DLA Piper
  • Susan Shiff, Ph.D., Sr. Vice President & Head of the Center for Observational & Real World Evidence, Merck & Co.
  • Jeffrey Stoll, Ph.D., Vice President, EY
  • BJ Tevelow, M.D., Sr. Partner, McKinsey & Company
  • Harry J. Travis, President & CEO, eTect, Inc., & Former Vice President, Aetna Specialty & Home Delivery Pharmacy
  • Robert Ward, President & CEO, Radius Health
  • Dieter Weinand, Member of the Board of Management of Bayer AG, President Pharmaceuticals & Chairman of the Board of Management of Bayer Pharma AG
Related Articles: